Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dachuang Cao

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 22, 2025
Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 TrialTheresa Hunter Gibble, Dachuang Cao, Xiaotian Michelle Zhang, et al.
Diabetes, Obesity & Metabolism|November 5, 2024
Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 studyKimberly A Gudzune, Adam Stefanski, Dachuang Cao, et al.
Diabetes Technology & Therapeutics|May 27, 2020
Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring SubstudyMaciej T Malecki, Dachuang Cao, Rong Liu, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 7, 2015
Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc AnalysisHaoda Fu, Dachuang Cao, Kristina S Boye, et al.
Diabetes, Obesity & Metabolism|June 4, 2020
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D studyLeslie Klaff, Dachuang Cao, Mary Anne Dellva, et al.
The New England Journal of Medicine|April 1, 2011
Growth hormone plus childhood low-dose estrogen in Turner's syndromeJudith L Ross, Charmian A Quigley, Dachuang Cao, et al.
Diabetes, Obesity & Metabolism|June 25, 2026
Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 TrialsAlexander Kokkinos, Tina Thethi, Clare J Lee, et al.
Primary Care Diabetes|November 28, 2018
Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sampleIskandar Idris, Kunal Gulati, Magaly Perez-Nieves, et al.
Postgraduate Medicine|March 25, 2018
Insulin non-persistence among people with type 2 diabetes: how to get your patients to stay on insulin therapyTheresa L Garnero, Nichola J Davis, Magaly Perez-Nieves, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 6, 2015
Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc AnalysisHaoda Fu, Dachuang Cao, Kristina S Boye, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 22, 2025
Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 TrialTheresa Hunter Gibble, Dachuang Cao, Xiaotian Michelle Zhang, et al.
Diabetes, Obesity & Metabolism|November 5, 2024
Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 studyKimberly A Gudzune, Adam Stefanski, Dachuang Cao, et al.
Diabetes Technology & Therapeutics|May 27, 2020
Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring SubstudyMaciej T Malecki, Dachuang Cao, Rong Liu, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 7, 2015
Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc AnalysisHaoda Fu, Dachuang Cao, Kristina S Boye, et al.
Diabetes, Obesity & Metabolism|June 4, 2020
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D studyLeslie Klaff, Dachuang Cao, Mary Anne Dellva, et al.
The New England Journal of Medicine|April 1, 2011
Growth hormone plus childhood low-dose estrogen in Turner's syndromeJudith L Ross, Charmian A Quigley, Dachuang Cao, et al.
Diabetes, Obesity & Metabolism|June 25, 2026
Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 TrialsAlexander Kokkinos, Tina Thethi, Clare J Lee, et al.
Primary Care Diabetes|November 28, 2018
Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sampleIskandar Idris, Kunal Gulati, Magaly Perez-Nieves, et al.
Postgraduate Medicine|March 25, 2018
Insulin non-persistence among people with type 2 diabetes: how to get your patients to stay on insulin therapyTheresa L Garnero, Nichola J Davis, Magaly Perez-Nieves, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 6, 2015
Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc AnalysisHaoda Fu, Dachuang Cao, Kristina S Boye, et al.
Pageof 5